Structure–Activity Relationship of N,N′-Disubstituted Pyrimidinetriones as CaV1.3 Calcium Channel-Selective Antagonists for Parkinson’s Disease-Reference-Cited by-同舟云学术

Structure–Activity Relationship of N,N′-Disubstituted Pyrimidinetriones as CaV1.3 Calcium Channel-Selective Antagonists for Parkinson’s Disease

Published:2013-05-23 Issue:11 Volume:56 Page:4786-4797
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Kang Soosung¹,Cooper Garry¹²,Dunne Sara Fernandez³,Luan Chi-Hao³,Surmeier D. James²,Silverman Richard B.¹

Affiliation:

1. Department of Chemistry, Department of Molecular Biosciences, Chemistry of Life Processes Institute, and Center for Molecular Innovation and Drug Discovery, Northwestern University, Evanston, Illinois 60208, United States

2. Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, United States

3. High-Throughput Analysis Laboratory, Northwestern University, Evanston, Illinois 60208, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm4005048

Reference33 articles.

1. L-type calcium channels and psychiatric disorders: A brief review

2. International Union of Pharmacology. XLVIII. Nomenclature and Structure-Function Relationships of Voltage-Gated Calcium Channels

3. L-Type Calcium Channels: The Low Down

4. Expression and 1,4-Dihydropyridine-Binding Properties of Brain L-Type Calcium Channel Isoforms

5. Structural and functional differences between L-type calcium channels: crucial issues for future selective targeting

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of striatal dopamine release by the L‐type calcium channel inhibitor isradipine co‐varies with risk factors for Parkinson's;European Journal of Neuroscience;2023-11-08

2. Quinpirole inhibits levodopa-induced dyskinesias at structural and behavioral levels: Efficacy negated by co-administration of isradipine;Experimental Neurology;2023-11

3. Ca_v1.3‐selective inhibitors of voltage‐gated L‐type Ca²⁺ channels: Fact or (still) fiction?;British Journal of Pharmacology;2023-03-14

4. The Role of Striatal Cav1.3 Calcium Channels in Therapeutics for Parkinson’s Disease;Voltage-gated Ca2+ Channels: Pharmacology, Modulation and their Role in Human Disease;2023

5. The role of voltage-gated calcium channels in the pathogenesis of Parkinson’s disease;International Journal of Neuroscience;2022-11-07